Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 1, 2001, Pages 15-21

  Boddy, A V ^a   Griffin, M J ^a   Sludden, J ^a   Thomas, H D ^a   Fishwick, K ^a   Wright, J G ^a   Plummer, Ruth E ^b   Highley, Martin ^b   Calvert, A H ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Infusion duration; Paclitaxel; Pharmacokinetics

Indexed keywords

ALCOHOL; CARBOPLATIN; CREMOPHOR; PACLITAXEL;

ALCOHOL BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CROSS-OVER STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TIME FACTORS;

EID: 0034913355     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100295     Document Type: Article

References (21)

1. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
2. Linearized colorimetric assay for Cremophor EL: Application to pharmacokinetics after 1-hour paclitaxel infusions
3. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
4. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
5. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
6. Nonlinear pharmacokinetic and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
7. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
8. Clinical pharmacokinetic and in vitro studies of nolatrexed dihydrochloride (AG337, THYMITAQ) and paclitaxel
9. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose sequencing study in patients with non-small-cell lung cancer
10. Pharmacokinetic models for the saturable distribution of paclitaxel
11. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC)
12. Phase I study of paclitaxel administered as a 1-hour infusion: Toxicity and pharmacokinetics
13. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
14. Clinical phase I study with one-hour paclitaxel infusion
15. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
16. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
17. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumours
18. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
19. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
20. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance - The causative role of improper dissolution of Cremophor EL
21. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients